Birth defects that involve the cerebral cortex -also known as malformations of cortical development (MCD) -are important causes of intellectual disability and account for 20-40% of drug-resistant epilepsy in childhood. High-resolution brain imaging has facilitated in vivo identification of a large group of MCD phenotypes. Despite the advances in brain imaging, genomic analysis and generation of animal models, a straightforward workflow to systematically prioritize candidate genes and to test functional effects of putative mutations is missing. To overcome this problem, an experimental strategy enabling the identification of novel causative genes for MCD was developed and validated. This strategy is based on identifying candidate genomic regions or genes via array-CGH or whole-exome sequencing and characterizing the effects of their inactivation or of overexpression of specific mutations in developing rodent brains via in utero electroporation. This approach led to the identification of the C6orf70 gene, encoding for a putative vesicular protein, to the pathogenesis of periventricular nodular heterotopia, a MCD caused by defective neuronal migration.
Introduction
The cerebral cortex plays a key role in cognitive and intellectual processes and is involved in emotional control as well as learning and memory. It is therefore not surprising that many neurological and psychiatric diseases result from malformations of cortical development (MCD). The etiology of MCD is complex since both acquired and genetic factors are involved. The cumulative prevalence of genetically determined proportion of MCD is about 2% and they are sporadic in most cases. For instance, the incidence of congenital brain dysgenesis was estimated to . Periventricular Nodular Heterotopia (PNH) is one of the most common MCDs and is caused by abnormal migration of neurons from the ventricular zone (VZ) to the developing cerebral cortex. The failure of neurons to migrate results in clusters of heterotopic neurons along the walls of the lateral ventricles which can usually be visualized using Magnetic Resonance Imaging (MRI). The clinical, anatomic and imaging features of PNH are heterogeneous. Nodules may range from small and unilateral to bilateral and symmetric. Common clinical sequelae include epilepsy and intellectual disabilities 3 . Mutations in the Filamin A (or FLNA) gene, which maps in Xq28, were found in 100% of families with Xlinked bilateral PNH and in 26% of sporadic patients 3, 4 . A rare, recessive form of PNH caused by mutations in the ARFGEF2 gene, which maps in 20q13, has been reported in two consanguineous families 5 . Recently, biallelic mutations in genes encoding the receptor-ligand cadherin pair DCHS1 and FAT4 have been identified in nine patients affected by a multisystemic disorder that includes PNH 6 . PNH has also been associated with fragile X syndrome 7 , Williams syndrome 8 , 22q11 microdeletion syndrome 9 , duplications at 5p15 10 , deletions at 1p36 11 , 5q14.3-q15 12 , 6p25 13 and 6q terminal deletion syndrome 14, 15, 16, 17, 18, 19 , suggesting that additional causative genes are scattered throughout the genome. However, for approximately 74% of sporadic PNH patients the genetic basis remains to be elucidated 17 .
Classical gene mapping approaches such as array Comparative Genomic Hybridization (array-CGH) have proven to be a powerful tools for the detection of sub-microscopic chromosomal abnormalities, however, the genomic regions identified using this approach are often large and contain numerous genes.
The advent of massive parallel sequencing techniques (i.e. Whole-Exome Sequencing (WES) and Whole-Genome sequencing (WGS)) has substantially reduced both the cost and the time required to sequence an entire human exome or genome. Nevertheless, interpretation of WES and WGS data remains challenging in the majority of cases, since for each patient tens to hundreds (or even thousands, depending from the type of analysis) variants emerge from data filtering.
To speed up the process of identifying novel MCD causative genes, a novel systematic strategy combining array-CGH, WES and in utero electroporation (IUE) screening of candidate genes was designed. IUE allows to selectively inactivate (or overexpress) specific genes or mutations in rodent brains, enabling rapid evaluation of their involvement in corticogenesis 18, 19 . RNAi mediated-knockdown or overexpression of one or more candidate genes is expected to cause, when the gene is associated with disease development, localized defects in neuronal migration and/or maturation. Upon the identification of a gene whose inactivation (or overexpression) reproduces the phenotype observed in patients in rodents, it becomes an outstanding candidate for the screening in sporadic patients with MCD. Using this approach, we recently revealed the crucial contribution of the C6orf70 gene (also known as ERMARD) in PNH pathogenesis in patients harbouring 6q27 chromosomal deletions 16 . . Filter synonymous variants and those observed at an allele frequency <5% and compare data with those from parental exomes to identify de novo variants.
Protocol

Plasmid DNA Preparation for In Utero Electroporation
1. Design several short hairpin RNAs (shRNAs) targeting either the coding sequence or the 3'UTR of the candidate genes as described previously 22 . 2. To prevent off target effects test shRNAs specificity by BLAST search against databases using standard methods. Exclude shRNAs displaying more than 50% of complementarity with other rat genes. 3. Clone annealed oligonucleotides into a mU6-pro vector as described previously 23 . 4. Purify plasmid DNA with a Maxi-prep according to manufacturer's instructions and make a final concentration of 3 µg/µL. 5. Aliquot 20 µl of DNA (0.5 mg/ml pCAGGS-GFP either alone or with 1.5 mg/ml of shRNA construct) and add 2 µL of Fast green dye (2 mg/mL) to allow visual monitoring of the injection.
In Utero Electroporation
1. Surgical procedure 1. Anesthetize E15.5 pregnant female rats (E0 was defined as the day of confirmation of sperm-positive vaginal plug), using a combination with a mixture of ketamine/xylazine (0.1 and 0.01 mg per body weight, respectively), which is given via an intraperitoneal injection for anesthetic induction. 2. Make sure that the animal is fully anesthetized by observing the disappearance of toe pinch reflex. 3. Shave the animal's lower abdomen using a clipper to remove the fur. Disinfect the skin using scrubs of povidone-iodine and 70%
alcohol. Apply veterinarian ointment on eyes to prevent dryness while under anaesthesia. 4. Place the animal on a heat source and put a sterile drape (with an open window of 4 -5 cm in the middle) over the incision site. Wear facemasks, lab coat, caps, and sterile surgical gloves. Maintain sterility until the end of the surgery. 5. Using sharp scissors to make a vertical incision (2 -2.5 cm) in the skin along the midline in the caudal abdomen and then make an incision of the muscle wall underneath the skin -also of 2.5 cm -along the midline. 6. Carefully expose one uterine horn from the abdominal cavity. Drop 37 °C pre-warmed normal saline solution to moisturize the embryos.
Keep the uterus moist all the time.
2. Injection of DNA and electroporation 1. Gently hold one of the uterine horns with ringed forceps and carefully push one embryo to the uterine wall. Hold the embryo in one hand and with the other hand insert carefully glass capillaries 1 mm from the midline into the left lateral ventricle (2-3 mm deep) and inject approximately 1 µL of DNA with Fast Green to allow visual monitoring of the injection using a microinjector. 2. Drop normal saline solution on the 3 x 7 mm 2 electrodes surface. Place the positive sterile electrode on the injected side (left lateral ventricle) and the negative sterile electrode on the right ventricle. Deliver 5 electrical pulses at 950 ms intervals with a foot-controlled pedal (4000 mF capacitor charged to 40 V with an electroporator).
3. Post electroporation procedures 1. Put back uterine horns to the abdominal cavity, add drops of normal saline solution to the cavity to allow embryos positioned more naturally and to account for intraoperative fluid loss. 2. Close the abdominal muscle wall with absorbable surgical sutures, then the skin using a simple-interrupted stitch. 3. Put the rat back to the cage and monitor the animal until it emerges from the anaesthesia. 4. For pain management administer buprenorphine (0.03 mg/kg) to the animal by a subcutaneous injection every 8 -12 h, for up to 48 h.
Representative Results
The experimental strategy designed to identify novel MCD causative genes is recapitulated in Figure 1 .
By performing array-CGH in a cohort of 155 patients with developmental brain abnormalities variably combining PNH (Figure 2A) , corpus callosum dysgenesis, colpocephaly, cerebellar hypoplasia and polymicrogyria associated with epilepsy, ataxia and cognitive impairment, we identified a 1.2 Mb minimal critical deletion in 6q27 shared by 12 patients (Figure 2B ) 21 . The genomic region contains four known genes (THBS2, PHF10, TCTE3 and DLL1) and two predicted genes (WDR27 and C6orf70) ( Figure 2B) .
In parallel to array-CGH, WES analysis in 14 patients with isolated bilateral PNH and no Copy Number Variations analysis was carried out, identifying one patient with a de novo mutation (c.752T>A: pIle250Asn) in the predicted C6orf70 gene (Genbank accession number NM_018341.1) (Figure 3) .
To confirm that the mutation identified in C6orf70 had a causative role in PNH and to investigate whether haploinsufficiency of the other genes mapping in 6q27 may influence the phenotype, their role in vivo on neuronal migration was explored using the in utero RNAi-mediated knockdown approach 23, 24 to silence their expression in rat cortical neural progenitors. Only genes expressed in the developing rat cortex, PHF10, C6orf70 and DLL1, were tested ( Figure 4A ). Different short hairpin RNAs (shRNAs) were generated targeting the coding sequences of these three genes. ShRNAs were then introduced into neuroprogenitors in the rat neocortex by in utero electroporation at embryonic day 15 (E15), when neurons committed to upper cortical layers are generated. Green fluorescent protein was used as transfection reporter.
Relative distribution of GFP-positive cells was examined 5 days after electroporation. Knockdown of Dll1 and Phf10 resulted in a slight delay of radial neuronal migration (data not shown), whereas knockdown of C6orf70 impaired neuronal migration and gave rise to the development of heterotopic nodules highly reminiscent of those observed in Flna knockdown model ( Figure 4B ) 24 In the past, researchers focused their efforts primarily on causative gene identification, leaving the design of functional assays to clarify their role in brain development to later stages. This has become more difficult due to the progression from the study of rare, recurrent genetic disorders to more common sporadic disorders for which traditional gene finding methods are not amenable. Current approaches to identify causative genes often allow the identification of relatively large regions of the genome containing numerous genes (array-CGH) or several variants in a number of candidate genes which are hard to validate (WES or WGS).
Array-CGH and WES (or WGS) approaches have broadened the mutation spectrum for many genetic disorders. Nevertheless, some critical limitations still remain. For instance, array-CGH needs high-quality DNA and fails to identify balanced translocations or small deletions/ duplications including those involving one or few exons of a single gene. To overcome this problem, array-CGH may be performed at a higher resolution than conventional probe spacing (e.g. using 1M array-CGH kit) or substituted with SNP-array analysis. WES often does not cover large intragenic regions and fails to identify deep intronic mutations. In addition, sometimes the coverage may be too low to identify causative mutations (especially in case of mutations with low percentage of mosaicism). Another critical step for WES is that data analysis and filtering still require a considerable effort. To increase the coverage of WES, the number of patients in a single experiment may be reduced or different capture kits may be used at the same time.
IUE is the most appropriate approach to analyse the impact of genes knockdown on neuronal migration. However, investigations on other steps of cortical developmental, such as neurogenesis and neuronal maturation, are hindered by some technical limitations. Indeed, IUE performed before E13 is often unsuccessful whereas investigations at later stages are restricted by the high rate of postnatal lethality associated to this procedure. In addition, gene-knockdown efficiency may differ among electroporated embryos leading to considerable phenotypic heterogeneity.
Overall, the present protocol has four major critical steps. Although it is not part of the protocol described in the present paper, we have to point out that the first fundamental step to be taken into account is the selection of patients to be enrolled in such studies. Indeed, the process of identifying novel MCD genes requires clinical and imaging investigations in a cohort of patients for whom the phenotype should be as homogeneous as possible. Collecting patients with highly homogeneous phenotype increases the chance of identifying causative mutations in a given gene. However, the minimum number of patients to be enrolled in such studies to achieve success is hard to predict, since it greatly depends on the mutation rate of the different genes. For example, for genes such as FLNA, which is mutated in 100% of familial cases of Xlinked bilateral PNH and in 26% of sporadic patients, the number of patients needed to identify multiple hits in the gene could be relatively low. Conversely, for genes with low mutation rate, the number of patients to be screened is higher. For example, in the case of C6orf70, we were able to identify a single causative mutation only upon screening 64 patients (14 through WES and 50 through conventional Sanger sequencing) 16 , estimating a mutation rate for this gene of about 1.5%. The second critical step is the exclusion of mutations in all known MCD genes in order to identify novel causative genes. Thanks to the advent of novel next generation sequencing technologies, mutation screening of known and candidate genes may now be performed in a single experiment. However, appropriate variants filtering should be used to avoid the presence of an excessive number of false positives to be experimentally confirmed and to filter out potential causative mutations. Indeed, the number of candidate genes/variants is particularly high in WES experiments. If the involvement of a given gene is suspected, mutation screening should also be complemented by MLPA analysis, to exclude microdeletions or microduplications. The third critical point is the fact that chromosomal rearrangements are strongly influenced by the location of the breakpoint. In this context, it is worth to exclude, to the greatest possible extent, the disruption or the displacement of cis-regulatory elements distal to genes not included into the deletion/duplication. Finally, in vivo RNAi experiments assume that causative genes play a direct role in neuronal migration during embryonic stages. However, the etiology of MCD, including PNH, is heterogeneous and the in utero approach could fail to detect the effects of genes involved in developmental steps including neuronal proliferation or cell survival. In addition, the low complexity of the rodent brain could mask the impact of the knockdown or the overexpression of a given candidate gene, which may be more evident in the human brain.
We believe that the integration of genomics and in vivo functional studies will help to develop new diagnostic tools for the identification of new MCD causative genes. This strategy could also provide new animal models to test therapeutic targets and understand the pathophysiology of MCD, which have so far been limited by the lack of experimental models and limited access to brain tissue from affected patients. Deciphering the molecular pathways that are associated with MCD disorders will also provide valuable new information about physiological brain development in general.
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